Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Gastaldi, R.
Right arrow Articles by Mandelli, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gastaldi, R.
Right arrow Articles by Mandelli, F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 13:1158-1160, 2002
© 2002 European Society for Medical Oncology

Letters to the Editor

Hodgkin’s disease in HIV-infected patients: report of eight cases usefully treated with doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) plus granulocyte colony- stimulating factor

R. Gastaldi*,1, P. Martino1, G. Gentile1, V. Picardi1, M. S. De Propris1, M. F. Pirillo2, A. De Vellis1 and F. Mandelli1

1 Ematologia, Dipartimento di Biotecnologie Cellulari ed Ematologia, University ‘La Sapienza’ of Rome, Via Benevento 6, 00161 Rome; 2 Virology, Istituto Superiore di Sanità of Rome, Italy (E-mail: gastaldi@bce.med.uniroma1.it)

The first 10% of the full text of this article appears below.

In the era prior to active antiretroviral therapy (HAART) and in the absence of growth factors, the response rates of HIV-infected people with Hodgkin’s disease (HD-HIV) with standard chemotherapy ranged between 45% and 70%. Median survival was only in the approximate range of 8–18 months. The underlying complications of HIV infection and the unfavourable clinical and biological characteristics are the major factors affecting survival of these patients [1]. The use of granulocyte colony-stimulating factor (G-CSF) concomitantly with standard ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) but without antiretroviral therapy failed to improve results . . . [Full Text of this Article]

Acknowledgements


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 ASH Education BookHome page
J. M. Connors
Challenging Problems: Coincident Pregnancy, HIV Infection, and Older Age
Hematology, January 1, 2008; 2008(1): 334 - 339.
[Abstract] [Full Text] [PDF]